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Oncolytic adenoviruses (Onc.Ads) selectively replicate in and lyse cancer cells and are therefore commonly used vectors in clinical trials for cancer gene therapy. Building upon the wellcharacterized adenoviral natural tropism, genetic modification of Onc.Ad can enhance/regulate their transduction and replication within specific cancer cell types. However, Onc.Admediated tumor cell lysis cannot fully eliminate tumors. The hostile tumor microenvironment provides many barriers to efficient oncolytic virotherapy, as tumors develop structure and immune-evasion mechanisms in order to grow and ultimately spread. For these reasons, Onc.Ads modified to deliver structural or immune modulatory molecules (Armed Onc.Ads) have been developed to overcome the physical and immunological barriers of solid tumors. The combination of oncolysis with tumor microenvironment modulation/ destruction may provide a promising platform for Ad-based cancer gene therapy. [3] . The US FDA recently approved T-VEC expressing granulocyte macrophage colony-stimulating factor (GM-CSF) to treat melanoma [4] . Treatment of advanced melanoma with T-VEC was safe and resulted in a 10.8% complete response rate, significantly higher than systemic administration of GM-CSF alone [5 ] . Thus, oncolytic virotherapy represents a new class of promising cancer immunotherapy agents. In this review, we will specifically discuss the application of adenoviral-based oncolytic viruses.
Introduction

Specific transduction and replication of oncolytic adenovirus in cancer cells
Oncolytic adenoviruses (Onc.Ads) have long been studied and tested in patients with malignancies without severe side effects and several clinical trials are ongoing (Table 1) [3]. For effective oncolytic activity, Onc.Ads must specifically infect and efficiently replicate within cancer cells; however, many cancer cells do not express or downregulate the coxsackie and adenovirus receptor (CAR), resulting in decreased transduction of serotype 5 Ad (Ad5), which is commonly used for Ad-based vectors [6] . Therefore, Ad5 fibers, the capsid moiety responsible for virus-cell surface receptor interaction, have been modified to increase their transduction to cancer cells. An RGD-motif inserted into the fiber knob increases viral interaction with integrins, which are highly expressed on some cancer cells, including prostate [7] and ovarian cancers [8] . Ad5 fiber has also been replaced by other serotype fibers to redirect to different receptors. For instance, serotype 35 fibers bind CD46 [9] , which is upregulated in breast and colorectal cancers, among others [10], while serotype 3 utilizes desmoglein 2, a component of the epithelial cell adhesion structure known to be overexpressed in multiple epithelial malignancies [11] . These fiber modifications have been utilized in both preclinical studies and clinical trials to enhance Onc.Ad transduction to malignant cells.
Onc.Ads have been genetically modified to allow for selective replication in cancer cells with abnormal protein expression patterns compared to normal cells. Adenovirus replication is initiated by E1A, the first adenoviral transcription unit. E1A gene products are responsible for dissociation of the retinoblastoma (Rb)/E2F complex, resulting in free transcription factor E2F activation of the remaining early transcription units, E1B, E2, E3, and E4 genes [12] . A commonly used Ad5-based Onc.Ad contains a 24 bp mutation in the E1A gene (E1AD24), which disrupts the retinoblastoma (Rb) binding domain and releases free E2F from Rb/E2F complex, resulting in an E1AD24 protein that cannot promote virus replication without free E2F [13] . Cancer cells, on the other hand, typically have high levels of free E2F resulting in the preferential replication of Onc.AdD24 in cancer cells. The Onc.Ads ICOVIR-5, -7, and -15 were developed to take advantage of excessive free E2F by regulating E1A transcription via the insertion E2F binding sites or E2F promoters [14] , and these ICOVIRs still harbor E1AD24 as an additional safety switch. Onc.Ads have also been generated by replacing the native E1A promoter with a tissue-specific or cancer cell-specific promoter such as the tCCN1 promoter, which is active in prostate cancer [15 ] . Although E1 gene regulation has improved cancer cell specific lysis and the safety of Onc.Ads in vitro and in preclinical xenograft models, human solid tumors are more complex, as discussed below.
Physical barriers to oncolytic adenovirus dissemination within solid tumors
Solid tumors are heterogeneous structures made up of malignant cells that recruit normal cells such as immune cells, fibroblasts, and endothelial cells to promote tumor growth (Figure 1) . Additionally, the presence of dense stromal tissue and high amounts of extracellular matrix (ECM) results in high fluid pressure in tumors, which inhibits the ability of Onc.Ads to spread throughout the tumor, thus limiting their effectiveness. Therefore, to enhance viral spread Armed Onc.Ads have been generated to target the ECM and angiogenesis. Onc.Ads expressing molecules such as relaxin [16] and hyaluronidase [17 ] to disrupt the ECM have shown promising preclinical results. Onc.Ad expressing relaxin, known to upregulate matrix metalloproteinases (MMPs), successfully increased viral spread in multiple tumor models [18] . VCN-01, an Onc.Ad armed with hyaluronidase, was able to decrease the presence of hyaluronic acid, a component of the ECM, and prolong survival in two orthotopic murine glioma models [17 ] . Contrastingly, Onc.Ads have also been armed with inhibitors of metalloproteinases (TIMPs), as these molecules inhibit the degradation of the ECM to affect tumor cell proliferation, migration, and angiogenesis. An Onc.Ad expressing TIMP2 had increased viral replication in primary ovarian tumor tissue; however, viral distribution was not evaluated [19] . Lucas et al. recently reported that a modification 10 Preventive/therapeutic vaccines Abbreviations: CD, cytosine deaminase; GM-CSF, granulocyte macrophage colony-stimulating factor; IFNg, interferon g; IMRT, intensity-modulated radiation therapy; IT, intratumoral; IV, intravenous; NSCLC, non-small cell lung cancer; TK, tyrosine kinase; w/, with; w/o, without.
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